Drug Profile
Research programme: uric acid depletion anti-gout therapeutics - DevaCell
Alternative Names: uriSHELSLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator DevaCell
- Class Enzymes; Oxidoreductases
- Mechanism of Action Urate oxidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gout
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Gout in USA (IM)
- 11 Aug 2016 Early research in Gout in USA (IM)